ArticleEClinicalMedicine2024
Once-weekly semaglutide versus placebo in adults with increased fracture risk: a randomised, double-blinded, two-centre, phase 2 trial.
Article in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04702516 (The Effect of Semaglutide), which is not on this map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Semaglutide (Ozempic) on Bone Turnover in Patients With Increased Fracture Risk: a Randomized Placebo-controlled Clinical Trial
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- GLP-1 Receptor Agonists and Musculoskeletal Outcomes: A Systematic Literature Review and Meta-Analysis.Drugs · 2026Pooled it
- The adverse effects associated with semaglutide use in patients at increased risk of cardiovascular events: a systematic review with meta-analysis and Trial Sequential Analysis.BMC medicine · 2025 · on this mapPooled it
- Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis.Acta diabetologica · 2025Pooled it
- Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme.European journal of heart failure · 2025Trial
- Trial
- Glucagon-like peptide-1: a critical link between gut microbiota dysbiosis and degenerative musculoskeletal diseases.Gut microbes · 2026Review
- Why Do We Lose Bone During Weight Loss: Can It Be Prevented?Current osteoporosis reports · 2026Review
- The Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review.Obesity (Silver Spring, Md.) · 2026Review
- Tirzepatide for Obesity in Adults ≥ 65 Years: A Post Hoc Analysis of the SURMOUNT and SUMMIT Clinical Trials.Diabetes, obesity & metabolism · 2026Article
- Musculoskeletal Outcomes of Glucagon-Like Peptide-1 Receptor Agonists Versus Other Antiobesity Agents in Nondiabetic Adults.Obesity (Silver Spring, Md.) · 2026Article
- Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation.Obesity pillars · 2026Review
- Letter to the Editor Regarding "Association Between Preoperative GLP-1 Receptor Analog Use and Postoperative Complications and Mortality Following Lumbar Fusion Surgery".Global spine journal · 2026Article
- Revisional Roux-en-Y gastric bypass after sleeve gastrectomy impacts bone health in postmenopausal women.Archives of osteoporosis · 2026Article
- GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.Stem cell reports · 2026Article
- Structured Exercise During and After Incretin-Based Pharmacotherapy Discontinuation: A Narrative Review of Mechanisms, Evidence, and Prescription Guidance.Healthcare (Basel, Switzerland) · 2026Review
- Integrating metabolic rehabilitation with incretin-based anti-obesity therapy: a narrative review of a multimodal strategy for sustainable weight loss.International journal of obesity (2005) · 2026Review
- Obesity-related bone fragility: An emerging clinical paradox.The Indian journal of medical research · 2026Article
- Negative effects of semaglutide on bone in obese mice.Cell reports. Medicine · 2026Article
- Lower fall and femoral fracture risks with semaglutide and tirzepatide compared with DPP-4 inhibitors in older adults with type 2 diabetes.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Oral Health Implications of GLP-1 Receptor Agonists and Other Incretin-Based Therapies.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Previous studies have indicated that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) may enhance bone formation and have neutral or beneficial effects on fracture risk. We evaluated the effect of the GLP-1RA semaglutide on the bone formation marker Procollagen type I N-terminal propeptide (PINP) in adults with increased fracture risk. Methods: This randomised, placebo-controlled, double-blinded, phase 2 clinical trial was conducted at two public hospitals in Denmark. We enrolled 64 men and women with increased fracture risk based on a T-score < -1.0 at the total hip or lumbar spine and/or low-energy fracture within three years of recruitment. Participants were randomised (1:1) to receive once-weekly subcutaneous semaglutide 1.0 mg or placebo. The primary outcome was changes in plasma (P)-PINP from baseline to week 52. Primary and safety outcomes were assessed and evaluated for all participants. This trial is complete and registered with ClinicalTrials.gov, NCT04702516. Findings: Between March 24 and December 8, 2021, 55 (86%) postmenopausal women and nine men with a mean age of 63 years (SD 5.5) and BMI of 27.5 kg/m Interpretation: In adults with increased fracture risk, semaglutide once weekly did not increase bone formation based on the bone formation marker P-PINP. The observed increase in bone resorption in the semaglutide group may be explained by the accompanying weight loss. Funding: Region of Southern Denmark, Novo Nordisk Foundation, and Gangsted Foundation. Novo Nordisk provided the investigational drug and placebo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.